Quick Answer
Enliven Therapeutics, Inc. reported Operating Income of -$119.66 million for fiscal year 2025.
Enliven Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$119.66M | -14.4% |
| 2024 | -$104.55M | -25.2% |
| 2023 | -$83.53M | -115.3% |
| 2022 | -$38.79M | +24.6% |
| 2021 | -$51.44M | -23.4% |
| 2020 | -$41.70M | -72.9% |
| 2019 | -$24.12M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$25.10M | +7.3% | +12.2% |
| June 30, 2025 | -$28.58M | -16.2% | +9.8% |
| March 31, 2025 | -$31.69M | -22.0% | -17.1% |
| September 30, 2024 | -$27.07M | -11.6% | -10.0% |
| June 30, 2024 | -$24.60M | -22.2% | +5.3% |
| March 31, 2024 | -$25.99M | -58.3% | -7.2% |
| September 30, 2023 | -$24.25M | -121.8% | -20.4% |
| June 30, 2023 | -$20.13M | -123.3% | -22.6% |
- Enliven Therapeutics, Inc. showed a decrease of -14.4% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Enliven Therapeutics, Inc.’s operating income has declined by 396.2% (from -$24.12 million to -$119.66 million).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: